CHMP positive opinions for AstraZeneca, Merck KGaA, Roche, Alcon and Merck-Serono
This article was originally published in Scrip
The November meeting of the Committee for Medicinal Products for Human Use (CHMP) only gave a positive opinion to one new medicine, AstraZeneca’s anticancer, Caprelsa (vandetanib), but recommended positive indications extensions for four other drugs: Merck KGaA’s Erbitux (cetuximab) in metastatic colorectal cancer; Roche’s herceptin (trastuzumab) in breast cancer; Alcon/Novartis’s Nevanac (nepafenac) in reducing the risk of macular oedema following cataract srgery; and Merck-Serono’s Rebif (interferon beta-1a) in early stages of multiple sclerosis.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.